|
| Home : Pieris Pharmaceuticals Announces Closing of Over-Allotment Option in Public Offering of Common Stock |
|
Jul 29
2015 |
Pieris Pharmaceuticals Announces Closing of Over-Allotment Option in Public Offering of Common Stock |
|
FREISING, GERMANY--(Marketwired - July 28, 2015) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, today announced that it closed the sale of an additional 1,211,827 shares of its common stock at the public offering price of $2.75 per share pursuant to the over-allotment option exercised by the underwriters of its recently completed public offering. Including proceeds from the exercise of the over-allotment option, total gross proceeds to Pieris from the offering were $28.3 million before deducting the underwriting discounts, commissions and estimated expenses. |
|
|
|
| Source:http://www.marketwired.com/mw/release.do?id=2042673&sourceType=3 |
| |
|
Related News
|
» Pelangio Exploration Announces Closing of Final Tranche of Private Placement for Proceeds of $89,190
» Cardiome Pharma Corp. Announces Approximately US$15.0 Million Bought Deal Financing
|
|
|
